INTRODUCTION {#s1}
============

As two tumor suppressor genes, *BRCA1* and *BRCA2* mutation are reported to have been associated with increased risk of developing ovarian cancer and breast cancer \[[@R1]--[@R3]\]. Both of them are involved in DNA damage repair through homologous recombination, contributing to genomic instability and malignant transformation \[[@R4]--[@R6]\]. Meanwhile, they also involved in cell growth inhibition, gene transcription regulation, apoptosis and other related cellular regulation processes. Previous study reported that patients with *BRCA*-deficient ovarian cancer had improved survival rates as these patients were reported sensitive to platinum-based chemotherapy \[[@R7], [@R8]\].

Currently, numerous studies have reported the association between *BRCA* mutations and ovarian cancer mortality, and the results are conflicting. Some investigators have found that ovarian cancer patients with *BRCA* mutations have more favorable outcomes \[[@R9]--[@R18]\], whereas others have indicated null results \[[@R7], [@R19]--[@R23]\].

Two previous published meta-analyses have reported the prognostic impact of *BRCA* mutations on ovarian cancer mortality \[[@R24], [@R25]\]. *Sun* et al. found that patients with ovarian cancer with *BRCA* dysfunction status tended to have a better outcome \[[@R24]\]. However, this study investigated the effects of *BRCA* dysfunction status including mutations, protein expression and its promoter methylation, which did not perform the detailed analyses of *BRCA* mutations. In the meta-analysis by *Zhong* et al. they only examined the *BRCA1* and *BRCA2* mutation separately with limited statistical power without examining *BRCA1/2* mutation \[[@R25]\]. Therefore, the purpose of this study was to update the meta-analysis on the impact of *BRCA* mutation carriers versus noncarriers on mortality in patients with ovarian cancer.

RESULTS {#s2}
=======

Literature search and study characteristics {#s2_1}
-------------------------------------------

From the initial literature search, we yielded 3595 citations. After exclusion of duplicate publications, 2624 citations remained for further review. 45 potentially eligible reports were selected when irrelevant studies were removed. After reading each full manuscript, we finally identified the 34 studies for meta-analysis. As is shown in Figure [1](#F1){ref-type="fig"}, we follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram to conduct this meta-analysis.

![Flowchart of the study selection](oncotarget-08-285-g001){#F1}

Characteristics of included studies {#s2_2}
-----------------------------------

Table [1](#T1){ref-type="table"} summarizes the baseline characteristics of the included studies. A total of 18,396 patients were included with 32 studies reporting the primary outcome of OS and 13 studies reporting the secondary outcome of PFS. *BRCA1*, *BRCA2* mutation and *BRCA1/2* mutation were reported in 15, 14 and 34 studies, respectively. All studies were published between 1996 and 2016. The mean study sample size was 541 (range 40 to 6556) with a percentage of serous cancer ranging from 24.2% to 100%. 32% (11/34) of the included study were conducted in Europe, 50% (17/34) in USA or Canada and 9% (3/34) in Asia, from which 13 were multicenter studies.

###### Baseline Characteristics of Included Studies

  Authors and published years   Study design   No. in study (cases/controls)   Inclusion period       Country of origin        Stage    Histology     serous cancer (%)   Mutation detection method   BRCA status   Germ /Soma   Single or multicenter   Follow-up Duration                                                                                                          Adjusted variables                                                                                  Mutation ratio   Optimal debulking(%)
  ----------------------------- -------------- ------------------------------- ---------------------- ------------------------ -------- ------------- ------------------- --------------------------- ------------- ------------ ----------------------- --------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------- ---------------- ----------------------
  Synowiec (2016)               RC             17/108                          2002-2008              Poland                   I-IV     all           54.4                PCR, seq                    BRCA1         Germ         single                  NR                                                                                                                          Age, stage, grade, histology, chemotherapy regimen, surgery, grade                                  13.60            61.6
  Sabatier (2016)               RC             33/71                           1994-2011              France                   I-IV     all           52.9                MLPA, DHPLC, Seq            BRCA1/2       Germ         single                  Mean 69.8 months with an s.d. of 58.4 months.                                                                               Age, stage, grade,histology, chemotherapy, surgery                                                  31.70            67.3
  Kotsopoulos (2016)            RC             177/1244                        1995-1999, 2002-2004   Canada                   I-IV     all           55.1                NR                          BRCA1/2       NR           single                  BRCA1 Mutation: 8.1 years (range0.94--20.2) BRCA2 Mutation: 7.6 years (range 2.08--19.9) WT: 9.7 years (range 0.59--20.3)   Age, stage, grade, histology, surgery                                                               12.50            NR
  Harter (2015)                 RC             97/567                          NR                     Germany                  II-IV    all           73.6                PCR, seq                    BRCA1/2       Germ         single                  NR                                                                                                                          Age, stage, grade, histology                                                                        15               NR
  Chen (2015)                   RC             61/195                          NR                     Finland                  NR       NR            NR                  PCR, Seq                    BRCA1/2       NR           multicenter             NR                                                                                                                          Age, grade, stage, residual disease, neoadjuvant therapy, primary therapy outcome                   23.82            NR
  Candido-dos-Reis (2015)       RC             1496/5060                       NR                     U.S.A                    I-IV     all           NR                  PCR, Seq                    BRCA1/2       Germ         multicenter             NR                                                                                                                          Stage, regional, and distant, histology, grade,                                                     22.80            NR
  Cunningham (2014)             RC             70/993                          1992-2011              U.S.A                    I-IV     all           73                  PCR, seq                    BRCA1/2       Germ+Soma    single                  Median 4.5 years (range 0.01-10)                                                                                            Age, stage, grade, debulking status, ascites present at surgery, menopausal status                  6.6              85
  Zhang (2014)                  RC             75/250                          2012                   NR                       II-IV    NR            NR                  PCR, seq                    BRCA1/2       NR           single                  NR                                                                                                                          Age, grade, stage, residual tumor size, response to chemotherapytherapy                             23.10            67.1
  Rudaitis (2014)               RC             55/52                           2008-2011              Lithuania                III-IV   nonmucinous   92.5                PCR, seq                    BRCA1/2       Germ         single                  BRCA1/2 Mutation: Median 35 months (range 1-169); BRCA1/2 WT; Median 25 months (range 8-210)                                Age,follow-up, ECOG, Histology, subtype, residual tumor size, neoadjuvant therapy, Family history   51.40            NR
  Pennington (2014)             RC             91/276                          NR                     U.S.A                    I-IV     all           70.3                PCR, seq                    BRCA1/2       Germ+Soma    multicenter             NR                                                                                                                          Age, site, grade, stage, residual tumor size                                                        24.8             66
  Safra (2013)                  RC             90/100                          1995-2009              U.S.A, Israeli, Italia   I-IV     all           69.5                PCR, Seq                    BRCA1/2       Germ         multicenter             Median 56 months (range 9.3--214)                                                                                           Age, stage, residual tumor size, Ethnicity, Institution                                             47.40            NR
  McLaughlin (2013)             RC             218/1408                        1995-1999, 2002-2004   Canada                   I-IV     all           55.8                PTT, DGGE, DHPLC, seq       BRCA1/2       Germ         multicenter             Mean 6.9 years (range 0.3-15.7)                                                                                             Age, histology, grade, stage                                                                        13.40            NR
  Hyman (2012)                  RC             47/143                          1996-2011              U.S.A                    III-IV   serous        100                 PCR, seq                    BRCA1/2       Germ         single                  Median 2.5 years                                                                                                            Age, stage, Optimal debulking, IP/IV                                                                24.70            76.3
  Dann (2012)                   RC             15/38                           1999-2007              U.S.A                    II-IV    all           73.6                PCR, seq                    BRCA1/2       Germ+Soma    single                  NR                                                                                                                          Age, grade, stage, histology, residual disease, chemotherapy, Platinum response                     28.30            83
  Chan (2012)                   RC             69/246                          NR                     U.S.A                    II-IV    serous        100                 PCR, seq                    BRCA1/2       Germ+Soma    single                  Median 35.4 months (range 1--125)                                                                                           Age, grade, stage, histology, residual disease, Ethnicity                                           21.80            65.8
  Alsop (2012)                  RC             141/860                         2002-2006              Australian               I-IV     all           70.8                PCR, seq                    BRCA1/2       Germ         single                  Median 63.4 months                                                                                                          Age, stage, grade, debulking, primary site, chemotherapy, Ethnicity                                 14.10            62.4
  Yang (2011)                   RC             62/252                          2009-2010              U.S.A                    II-IV    serous        100                 PCR, seq                    BRCA1/2       Germ+Soma    single                  NR                                                                                                                          Age, stage, grade, debulking, Ethnicity                                                             19.70            65.8
  Lacour (2011)                 RC             95/183                          1996-2007              U.S.A                    III-IV   all           68                  PCR, seq                    BRCA1/2       NR           multicenter             BRCA Mutation; median 42.6 ; BRCA WT; median 37.5                                                                           Age, stage, grade, histology, debulking, response to chemotherapy, Institution, Ethnicity           34.20            70.1
  Gallagher (2011)              RC             36/74                           1996-2006              U.S.A                    III-IV   all           80.9                PCR, Seq                    BRCA1/2       Germ         single                  Median 41 months                                                                                                            Age, stage, histology, debulking, platinum response, CA125, secondary cytoreduction                 32.70            60.9
  Hennessy (2010)               RC             44/191                          1996-2006              U.S.A                    I-IV     all           79.1                PCR,Seq                     BRCA1/2       Germ+Soma    multicenter             Median 1071days (range 19-6241)                                                                                             Age, grade, stage, residual disease, surgery, chemotherapy                                          18.70            58.7
  Tan (2008)                    NCC            22/44                           1993-1995              UK                       II-IV    all           81.8                SCCP, seq                   BRCA1/2       Germ         multicenter             NR                                                                                                                          Age, stage, histology                                                                               33.30            NR
  Chetrit (2008)                RC             225/554                         1994-1999              Israel                   I-IV     all           57.1                PCR, seq                    BRCA1/2       Germ         single                  Median 6.2 years (range 4.2-9.4)                                                                                            Age, stage, grade, menopausal status                                                                28.90            NR
  Pal (2007)                    RC             32/200                          2000-2003              U.S.A                    I-IV     all           57.9                PCR, seq                    BRCA1/2       Germ         single                  NR                                                                                                                          Age, grade, stage, histology                                                                        13.80            NR
  Majdak (2005)                 NCC            18/187                          1994-2002              Poland                   I-IV     all           64.9                F-CSGE, PCR, Seq            BRCA1/2       Germ         single                  NR                                                                                                                          Age, stage, grade, histology, residual, outcome, Infertility                                        8.8              52.2
  Cass (2003)                   RC             34/37                           1990-1998              U.S.A                    I-IV     all           84.5                PCR, SSCR, seq              BRCA1/2       Germ         single                  Median 72months                                                                                                             Age, stage, grade, histology, CA125, optimal cytoreduction, Primary chemotherapy,                   47.90            NR
  David (2002)                  RC             234/662                         1994-1999              Israel                   NR       all           NR                  SCCP,seq                    BRCA1/2       Germ         single                  Median 30.5 months(range 20-64)                                                                                             age, stage, family history                                                                          26.10            NR
  Buller (2002)                 NCC            24/48                           NR                     U.S.A                    I-IV     all           74.6                PCR,PTT, seq, SSCP          BRCA1         Germ+Soma    single                  NR                                                                                                                          /                                                                                                   23.60            NR
  Zweemer (2001)                NCC            23/17                           NR                     Netherland               I-IV     all           55                  PCR,PTT                     BRCA1/2       Germ         single                  Mean 47 months (range 6-168)                                                                                                age, stage, grade                                                                                   57.50            NR
  Ramus (2001)                  RC             27/71                           1992-1997              Israel                   I-IV     all           77.6                RCR, SSCP, seq              BRCA1/2       Germ         single                  NR                                                                                                                          /                                                                                                   27.60            NR
  Boyd (2000)                   RC             88/101                          1986-1998              U.S.A                    I-IV     all           64                  PCR, Seq                    BRCA1/2       Germ         multicenter             BRCA Mutation; median 57 months; BRCA WT; median 59 months                                                                  Histology, grade, stage, cytoreductive surgery, chemotherapy                                        46.60            50.8
  Pharoah (1999)                NCC            38/127                          NR                     UK                       I-IV     all           24.2                PTT, SSCP, Seq              BRCA1/2       Germ         multicenter             NR                                                                                                                          /                                                                                                   56               NR
  Johannsson (1998)             NCC            38/97                           1985-1995              Sweden                   I-IV     all           NR                  PTT, SSCP, Seq              BRCA1         Germ         multicenter             NR                                                                                                                          /                                                                                                   28.15            NR
  Aida (1998)                   NCC            13/49                           1983-1997              Japan                    III      all           83.9                SSCP, PCR, Seq              BRCA1         Germ         multicenter             Mean 54.8 months                                                                                                            Age, histology, stage, chemotherapy, response,                                                      57.80            NR
  Rubin (1996)                  NCC            43/43                           1998-1996              U.S.A                    III-IV   all           81.1                SSCP, PCR, Seq              BRCA1         Germ         multicenter             Mean 71 months                                                                                                              /                                                                                                   50               NR

Abbreviations: DGGE = fluorescent multiplex denaturing gradient gel electrophoresis; DHPLC = Denaturing high performance liquid chromatography; F-CSGE = Fluorescence-based Conformation Sensitive Gel Electrophoresis; Germ = germline mutation; IP= combined intravenous and intraperitoneal therapy; IV= intravenous therapy alone; MLPA = multiplex ligation-dependent probe amplification; NCC=Nested case-control study; NR=not reported; PTT = Protein truncation test; RC=retrospective cohort; RFLP = Restriction fragment length polymorphisms; seq = sequencing; Soma = somatic mutation; SSCP = Single-Strand Conformation Polymorphism;

As shown in [Supplementary Table S1](#SD1){ref-type="supplementary-material"}, the quality of the 34 included studies was generally high with 17 studies being more than 7 points.

Survival analysis for *BRCA1/2*-mutation carriers with ovarian cancer {#s2_3}
---------------------------------------------------------------------

### OS analysis {#s2_3_1}

32 studies of 17,497 patients with either *BRCA1* or *BRCA2*-mutation (*BRCA1/2*-mutation) were identified in this analysis. Patients with *BRCA1/2*-mutation had significant OS benefit (HR = 0.67, 95% CI, 0.57 to 0.78, I^2^ = 76.5%, *P* \< 0.001; Figure [2A](#F2){ref-type="fig"}).

###### 

(**A**) Forest plot for the association between *BRCA1/2* mutation and ovarian cancer (1) overall survival and (2) progression-free survival. (**B**) Forest plot for the association between *BRCA1* mutation and ovarian cancer overall survival and progression-free survival; (**C**) Forest plot for the association between *BRCA2* mutation and ovarian cancer overall survival and progression-free survival.
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Subgroup analyses revealed that studies with adequate adjusted variables, but not with inadequate adjusted variables had statistically significant OS benefit in ovarian cancer patients with *BRCA1/2*-mutation (adequate adjusted variables, HR = 0.63, 95% CI, 0.53 to 0.75, I^2^ = 80.7%, *P* \< 0.001; inadequate adjusted variables, HR = 0.89, 95% CI, 0.72 to 1.10, I^2^ = 0, *P* = 0.992). OS benefits were also indicated in other subgroups and the HRs for all of the different subgroups are summarized in Table [2A](#T2a){ref-type="table"}.

###### Subgroup analyses stratified by some of the baseline characteristics for associations between *BRCA1/2* mutation and overall survival

                                               HR     95%CI          Degree of heterogeneity (I^2^ statistics; %)   *P*        No. of included Studies
  -------------------------------------------- ------ -------------- ---------------------------------------------- ---------- -------------------------
  Total                                                                                                                        
                                               0.67   0.57 to 0.78   76.5                                           \< 0.001   32
  Study quality                                                                                                                
  Score \> 7                                   0.67   0.56 to 0.80   74.4                                           \< 0.001   15
    ≤ 7                                        0.66   0.50 to 0.87   79.2                                           \< 0.001   17
  Stage of disease                                                                                                             
   I-IV                                        0.79   0.66 to 0.94   76.5                                           \< 0.001   19
   II-IV                                       0.47   0.37 to 0.59   0                                              0.423      5
   III-IV                                      0.64   0.49 to 0.83   43.2                                           \< 0.091   8
  Study design                                                                                                                 
   Cohort                                      0.67   0.56 to 0.79   80.1                                           \< 0.001   24
   Case-control                                0.65   0.44 to 0.96   56.7                                           0.024      8
  Sample size                                                                                                                  
    ≥ 200                                      0.68   0.56 to 0.83   85.5                                           \< 0.001   5
    \< 200                                     0.67   0.54 to 0.83   45.7                                           0.021      17
  Research center                                                                                                              
   Single                                      0.67   0.53 to 0.84   76.7                                           \< 0.001   20
   Multicenter                                 0.70   0.57 to 0.86   75.5                                           \< 0.001   11
  Duration of follow-up Months                                                                                                 
    \> 60                                      0.77   0.65 to 0.91   77.7                                           \< 0.001   20
    ≤ 60                                       0.58   0.49 to 0.68   40.7                                           0.069      12
  Adequate baseline characteristics adjusted                                                                                   
   Yes                                         0.63   0.53 to 0.75   80.7                                           \< 0.001   26
   No                                          0.89   0.72 to 1.10   0                                              0.922      6
  Histology                                                                                                                    
   All                                         0.68   0.58 to 0.79   76.2                                           \< 0.001   31
   High-grade serous                           0.62   0.43 to 0.90   84                                             \< 0.001   4
  Mutation ratio                                                                                                               
    \> 25%                                     0.70   0.60 to 0.81   36.3                                           0.068      17
    ≤ 25%                                      0.65   0.51 to 0.82   85.5                                           \< 0.001   15
  Region                                                                                                                       
   Europe                                      0.65   0.48 to 0.88   64.8                                           0.002      10
   America/Canada                              0.72   0.59 to 0.89   80.3                                           \< 0.001   16
   Asia                                        0.69   0.51 to 0.93   12.0                                           0.321      3
  Optimal debulking ratio                                                                                                      
    \> 65%                                     0.58   0.48 to 0.72   41.6                                           0.090      9
    ≤ 65%                                      0.53   0.35 to 0.79   60.9                                           0.037      5

Abbreviations: HR = hazard ratio; CI = confidence interval.

###### Subgroup analyses stratified by some of the baseline characteristics for associations between *BRCA1* mutation and overall survival

                                               HR     95%CI          Degree of heterogeneity (I^2^ statistics; %)   *P*     No. of included Studies
  -------------------------------------------- ------ -------------- ---------------------------------------------- ------- -------------------------
  Total                                        0.73   0.63 to 0.86   34.8                                           0.090   15
  Study quality                                                                                                             
  Score \> 7                                   0.76   0.63 to 0.91   35.2                                           0.137   9
    ≤ 7                                        0.66   0.47 to 0.91   44.6                                           0.108   6
  Stage of disease                                                                                                          
   I--IV                                       0.72   0.58 to 0.88   47.1                                           0.057   9
   II--IV                                      0.79   0.49 to 1.27   0                                              0.816   2
   III--IV                                     0.69   0.46 to 1.04   50.2                                           0.110   4
  Study design                                                                                                              
   Cohort                                      0.73   0.63 to 0.86   22.6                                           0.221   12
   Case-control                                0.54   0.24 to 1.24   69.9                                           0.036   3
  Sample size                                                                                                               
    ≥ 200                                      0.76   0.64 to 0.92   33.3                                           0.152   9
    \< 200                                     0.65   0.47 to 0.90   46.2                                           0.098   6
  Research center                                                                                                           
   Single                                      0.77   0.65 to 0.90   0                                              0.461   9
   Multicenter                                 0.69   0.52 to 0.91   63.6                                           0.017   6
  Duration of follow-up Months                                                                                              
    \> 60                                      0.74   0.61 to 0.88   51.5                                           0.029   10
    ≤ 60                                       0.68   0.47 to 0.99   0                                              0.645   5
  Adequate baseline characteristics adjusted                                                                                
   Yes                                         0.70   0.59 to 0.83   35.5                                           0.099   13
   No                                          0.93   0.71 to 1.21   0                                              0.568   2
  Histology                                                                                                                 
   All                                         0.70   0.59 to 0.83   35.5                                           0.099   13
  High-grade serous                            0.78   0.53 to 1.14   74.0                                           0.009   4
  Region                                                                                                                    
   Europe                                      0.82   0.64 to 1.06   44.3                                           0.166   3
   America/Canada                              0.77   0.62 to 0.96   31.2                                           0.190   7
   Asia                                        0.48   0.20 to 1.19   27.1                                           0.242   2

Abbreviations: HR=hazard ratio; CI= confidence interval.

###### Subgroup analyses stratified by some of the baseline characteristics for associations between *BRCA2* mutation and overall survival

                                               HR     95%CI          Degree of heterogeneity (I^2^ statistics; %)   *P*     No. of included Studies
  -------------------------------------------- ------ -------------- ---------------------------------------------- ------- -------------------------
  Total                                        0.57   0.45 to 0.73   50.3                                           0.016   14
  Study quality                                                                                                             
   Score \> 7                                  0.53   0.40 to 0.70   50.2                                           0.034   10
    ≤ 7                                        0.71   0.41 to 1.21   46.7                                           0.131   4
  Stage of disease                                                                                                          
   I--IV                                       0.56   0.43 to 0.74   39.6                                           0.103   9
   II--IV                                      0.46   0.21 to 0.97   37.2                                           0.207   2
   III--IV                                     0.64   0.32 to 1.28   64.0                                           0.062   3
  Study design                                                                                                              
   Cohort                                      0.56   0.43 to 0.72   48.3                                           0.030   12
   Case-control                                0.54   0.13 to 2.14   70.7                                           0.065   2
  Sample size                                                                                                               
    ≥ 200                                      0.54   0.41 to 0.73   51.4                                           0.036   9
    \< 200                                     0.63   0.38 to 1.04   52.9                                           0.075   5
  Research center                                                                                                           
   Single                                      0.52   0.39 to 0.70   24.6                                           0.224   9
   Multicenter                                 0.65   0.43 to 0.89   71.5                                           0.007   5
  Duration of follow-up Months                                                                                              
    \> 60                                      0.59   0.44 to 0.78   55.8                                           0.016   10
    ≤ 60                                       0.52   0.28 to 0.94   45.4                                           0.139   4
  Adequate baseline characteristics adjusted                                                                                
   Yes                                         0.52   0.40 to 0.68   48.7                                           0.029   12
   No                                          0.92   0.61 to 1.39   0                                              0.881   2
  Histology                                                                                                                 
   All                                         0.56   0.44 to 0.72   36.7                                           0.097   12
   High-grade serous                           0.54   0.32 to 0.93   79.8                                           0.002   4
  Region                                                                                                                    
   Europe                                      0.61   0.34 to 1.07   59.0                                           0.087   3
   America/Canada                              0.51   0.34 to 0.76   66.5                                           0.006   7
   Asia                                        0.88   0.44 to 1.75   /                                              /       1

Abbreviations: HR = hazard ratio; CI = confidence interval.

### PFS analysis {#s2_3_2}

We identified 13 studies involving 3,485 patients with *BRCA1/2*-mutation for analysis of PFS \[[@R7], [@R10], [@R13], [@R20], [@R26]--[@R34]\]. Patients with *BRCA1/2*-mutation had significant PFS benefit (HR = 0.62, 95% CI, 0.53 to 0.73, I^2^ = 18.1%, *P* = 0.261; Figure [2A](#F2){ref-type="fig"}). The results of subgroup analyses for the association between *BRCA1/2*-mutation and PFS are demonstrated in Table [3A](#T3a){ref-type="table"}. In summary, *BRCA1/2*-mutation was significantly associated with improved PFS for studies stratified according to study quality, study design, number of research center, tumor histology and study region. The trend toward an improved PFS was also observed when studies were stratified by tumor stage, sample size, duration of follow-up and optimal debulking ratio.

###### Subgroup analyses stratified by some of the baseline characteristics for associations between *BRCA1/2* mutation and progression-free survival

                                               HR     95%CI          Degree of heterogeneity (I^2^ statistics; %)   *P*     No. of included Studies
  -------------------------------------------- ------ -------------- ---------------------------------------------- ------- -------------------------
  Total                                                                                                                     
                                               0.62   0.53 to 0.73   18.1                                           0.261   13
  Study quality                                                                                                             
   Score \> 7                                  0.65   0.52 to 0.81   40.9                                           0.118   7
   ≤ 7                                         0.59   0.46 to 0.75   0                                              0.523   6
  Stage of disease                                                                                                          
   I--IV                                       0.74   0.47 to 1.15   63.0                                           0.044   4
   II--IV                                      0.55   0.43 to 0.69   0                                              0.520   5
   III--IV                                     0.60   0.48 to 0.76   0                                              0.996   4
  Study design                                                                                                              
   Cohort                                      0.64   0.55 to 0.74   15.9                                           0.296   10
   Case-control                                0.44   0.22 to 0.86   4                                              0.271   3
  Sample size                                                                                                               
   ≥ 200                                       0.61   0.51 to 0.72   0                                              0.996   6
   \< 200                                      0.62   0.37 to 1.04   60.7                                           0.026   6
  Research center                                                                                                           
   Single                                      0.65   0.54 to 0.78   24                                             0.230   9
   Multicenter                                 0.56   0.42 to 0.75   10.7                                           0.340   4
  Duration of follow-up Months                                                                                              
   \> 60                                       0.60   0.30 to 1.18   74.6                                           0.005   4
   ≤ 60                                        0.60   0.51 to 0.70   42.2                                           0.995   7
  Adequate baseline characteristics adjusted                                                                                
   Yes                                         0.62   0.53 to 0.73   18.1                                           0.261   13
   No                                          /      /              /                                              /       0
  Histology                                                                                                                 
   All                                         0.64   0.52 to 0.78   28.4                                           0.175   11
   High-grade serous                           0.60   0.40 to 0.89   /                                              /       1
  Mutation ratio                                                                                                            
   \> 25%                                      0.60   0.51 to 0.71   0                                              0.987   6
   ≤ 25%                                       0.63   0.43 to 0.92   55.6                                           0.036   7
  Region                                                                                                                    
   Europe                                      0.63   0.40 to 0.98   70.7                                           0.008   5
   America/Canada                              0.59   0.48 to 0.73   0                                              0.985   5
   Asia                                        0.75   0.08 to 6.90   /                                              /       1
  Optimal debulking ratio                                                                                                   
   \> 65%                                      0.70   0.50 to 1.00   55.1                                           0.063   5
   ≤ 65%                                       0.63   0.50 to 0.79   0                                              0.938   3

Abbreviations: HR = hazard ratio; CI = confidence interval.

###### Subgroup analyses stratified by some of the baseline characteristics for associations between *BRCA1* mutation and progression-free survival

                                               HR     95%CI          Degree of heterogeneity (I^2^ statistics; %)   *P*     No. of included Studies
  -------------------------------------------- ------ -------------- ---------------------------------------------- ------- -------------------------
  Total                                                                                                                     
                                               0.68   0.52 to 0.89   0                                              0.750   3
  Study quality                                                                                                             
   Score \> 7                                  0.78   0.48 to 1.27   0                                              0.709   2
   ≤ 7                                         0.64   0.46 to 0.88   /                                              /       1
  Stage of disease                                                                                                          
   I--IV                                       0.64   0.46 to 0.88   /                                              /       1
   II--IV                                      0.78   0.48 to 1.27   0                                              0.709   2
   III--IV                                     /      /              /                                              /       0
  Study design                                                                                                              
   Cohort                                      0.68   0.52 to 0.89   0                                              0.750   3
   Case-control                                /      /              /                                              /       0
  Sample size                                                                                                               
   ≥ 200                                       0.68   0.52 to 0.89   0                                              0.750   3
   \< 200                                      /      /              /                                              /       0
  Research center                                                                                                           
   Single                                      0.68   0.52 to 0.89   0                                              0.750   3
   Multicenter                                 /      /              /                                              /       0
  Duration of follow-up Months                                                                                              
   \> 60                                       0.64   0.46 to 0.88   /                                              /       1
   ≤ 60                                        0.78   0.48 to 1.27   0                                              0.709   2
  Adequate baseline characteristics adjusted                                                                                
   Yes                                         0.68   0.52 to 0.89   0                                              0.750   3
   No                                          /      /              /                                              /       0
  Histology                                                                                                                 
   All                                         0.70   0.59 to 0.83   35.5                                           0.099   2
   High-grade serous                           0.81   0.48 to 1.37   /                                              /       1
  Region                                                                                                                    
   Europe                                      /      /              /                                              /       0
   America/Canada                              0.81   0.48 to 1.38   /                                              /       1
   Asia                                        /      /              /                                              /       0

Abbreviations: HR = hazard ratio; CI = confidence interval.

###### Subgroup analyses stratified by some of the baseline characteristics for associations between *BRCA2* mutation and progression-free survival

                                               HR     95%CI          Degree of heterogeneity (I^2^ statistics; %)   *P*     No. of included Studies
  -------------------------------------------- ------ -------------- ---------------------------------------------- ------- -------------------------
  Total                                                                                                                     
                                               0.48   0.30 to 0.75   0                                              0.590   3
  Study quality                                                                                                             
   Score \> 7                                  0.41   0.24 to 0.70   0                                              0.895   2
   ≤ 7                                         0.68   0.30 to 1.55   /                                              /       1
  Stage of disease                                                                                                          
   I--IV                                       0.68   0.30 to 1.55   /                                              /       1
   II--IV                                      0.41   0.24 to 0.70   0                                              0.895   2
   III--IV                                     /      /              /                                              /       0
  Study design                                                                                                              
   Cohort                                      0.48   0.30 to 0.75   0                                              0.590   3
   Case-control                                /      /              /                                              /       0
  Sample size                                                                                                               
   ≥ 200                                       0.48   0.30 to 0.75   0                                              0.590   3
   \< 200                                      /      /              /                                              /       0
  Research center                                                                                                           
   Single                                      0.48   0.30 to 0.75   0                                              0.590   3
   Multicenter                                 /      /              /                                              /       0
  Duration of follow-up Months                                                                                              
   \> 60                                       0.68   0.30 to 1.55   /                                              /       1
   ≤ 60                                        0.41   0.24 to 0.70   0                                              0.895   2
  Adequate baseline characteristics adjusted                                                                                
   Yes                                         0.48   0.30 to 0.75   0                                              0.590   3
   No                                          /      /              /                                              /       0
  Histology                                                                                                                 
   All                                         0.40   0.22 to 0.73   /                                              /       1
   High-grade serous                           0.60   0.30 to 1.20   0                                              0.576   2
  Region                                                                                                                    
   Europe                                      /      /              /                                              /       0
   America/Canada                              0.40   0.22 to 0.74   /                                              /       1
   Asia                                        /      /              /                                              /       0

Abbreviations: HR = hazard ratio; CI = confidence interval.

No evident publication bias was observed by funnel plot asymmetry (Figure [3A](#F3){ref-type="fig"}) or through Begg\'s test (OS, *P* = 0.72; PFS, *P* = 0.58) or Egger\'s test (OS, *P* = 0.23; PFS, *P* = 0.93). The trim and fill method applied to further conduct the sensitivity analysis indicated 8 and 5 missing studies in the funnel plot for OS and PFS, respectively (Figure [3](#F3){ref-type="fig"}). However, imputing these hypothesized studies did not substantially alter the primary pooled estimates (OS, adjusted HR = 0.49, 95% CI 0.41 to 0.59; PFS, adjusted HR = 0.48, 95% CI 0.40 to 0.58).

![Funnel plot for (**A**) *BRCA1/2*, (**B**) *BRCA1,* (**C**) *BRCA2* mutation and ovarian cancer overall survival and/or progression-free survival](oncotarget-08-285-g003){#F3}

Survival analysis for *BRCA1*-mutation carriers with ovarian cancer {#s2_4}
-------------------------------------------------------------------

### OS analysis {#s2_4_1}

15 studies involving 12,995 patients with *BRCA1*-mutation were identified for meta-analysis \[[@R12], [@R13], [@R27], [@R28], [@R32], [@R34]--[@R43]\]. Patients with *BRCA1*-mutation had significant OS benefit (HR = 0.73, 95% CI, 0.63 to 0.86, I^2^ = 34.8%, *P* \< 0.001; Figure [2B](#F2){ref-type="fig"}).

The results of subgroup analyses for the association between *BRCA1*-mutation and PFS are presented in Table [2B](#T2b){ref-type="table"}. We found that ovarian cancer patients with *BRCA1*-mutation had significantly longer OS than non-carriers, regardless of study quality, sample size, research center or duration of follow-up. Such trend was also noted in studies with cohort study design, adequate baseline characteristics adjusted, all histologic types or conducted in USA or Canada.

### PFS analysis {#s2_4_2}

We identified 3 studies involving 1,640 patients with *BRCA1*-mutation for analysis of PFS \[[@R13], [@R27], [@R28]\]. Patients with *BRCA1*-mutation had significant PFS benefit (HR = 0.68, 95% CI, 0.52 to 0.89, I^2^ = 0, *P* \< 0.001; Figure [2B](#F2){ref-type="fig"}). The results of subgroup analyses for the association between *BRCA1*-mutation and PFS are demonstrated in Table [3B](#T3b){ref-type="table"}.

No evident publication bias was observed by funnel plot asymmetry (Figure [3B](#F3){ref-type="fig"}) or through Egger\'s test (*P* = 0.84) or Begg\'s test (*P* = 0.83) for OS. The trim and fill method applied to further conduct the sensitivity analysis indicated one missing study in the funnel plot for OS (Figure [3](#F3){ref-type="fig"}). However, imputing this hypothesized study did not alter the primary pooled estimates (adjusted HR = 0.66, 95 % CI, 0.56 to 0.78). We did not investigate the publication bias for PFS due to the limited number of studies.

Survival analysis for *BRCA2*-mutation carriers with ovarian cancer {#s2_5}
-------------------------------------------------------------------

### OS analysis {#s2_5_1}

14 studies including 12,933 patients with *BRCA2*-mutation were involved for meta-analysis \[[@R12], [@R13], [@R27], [@R28], [@R32], [@R35]--[@R43]\]. Patients with *BRCA2*-mutation had significant OS benefit (HR = 0.57, 95% CI, 0.45 to 0.73, I^2^ = 50.3%, *P* \< 0.001; Figure [2C](#F2){ref-type="fig"}).

The results of subgroup analyses for the association between *BRCA2*-mutation and OS are presented in Table [2C](#T2c){ref-type="table"}. We found that ovarian cancer patients with *BRCA2*-mutation had significantly longer OS than non-carriers, regardless of research center, duration of follow-up or histologic type. Such trend was also noted in studies with high quality, II-IV disease stage, cohort study design, sample size larger than 200, adequate baseline characteristics adjusted or conducted in USA or Canada.

### PFS analysis {#s2_5_2}

We identified 3 studies involving 1,640 patients with *BRCA2*-mutation for analysis of PFS \[[@R13], [@R27], [@R28]\]. Patients with *BRCA2*-mutation had significant PFS benefit (HR = 0.48, 95% CI, 0.30 to 0.75, I^2^ = 0, *P* \< 0.001; Figure [2C](#F2){ref-type="fig"}). The results of subgroup analyses for the association between *BRCA2*-mutation and PFS are demonstrated in Table [3C](#T3c){ref-type="table"}.

No evident publication bias was observed by funnel plot asymmetry (Figure [3C](#F3){ref-type="fig"}) or through Egger\'s test (*P* = 0.54) or Begg\'s test (*P* = 0.96) for OS. The trim and fill method applied to further conduct the sensitivity analysis indicated 4 missing studies in the funnel plot for OS (Figure [3](#F3){ref-type="fig"}). However, imputing these hypothesized studies did not alter the primary pooled estimates (adjusted HR = 0.38, 95 % CI 0.29 to 0.50). We did not investigate the publication bias for PFS due to the limited number of studies.

DISCUSSION {#s3}
==========

The aim of this meta-analysis was to examine the association between *BRCA* mutation status and ovarian cancer survival (OS and PFS). By pooling the outcomes of 18,396 ovarian cancer patients from 34 individual studies, we found that *BRCA* mutation (*BRCA1/2*, *BRCA1* and *BRCA2*) carriers had significantly improved OS and PFS benefits in ovarian cancer patients. Subgroup analysis revealed that this survival benefits remained constant irrespective of study quality, tumor stage, study design, sample size, number of research center, duration of follow-up, baseline characteristics adjusted and tumor histology.

This meta-analysis showed that patients who were *BRCA* mutation carriers had a 33%, 27% and 43% reduction in all-cause mortality for *BRCA1/2*, *BRCA1* and *BRCA2* mutants respectively, while patients had a 38%, 32% and 52% reduction in progression-free mortality for *BRCA1/2*, *BRCA1* and *BRCA2* mutants, respectively. Individually, however, some of the studies had reported contradictory findings \[[@R7], [@R19]--[@R22]\]: some studies have indicated significantly reduced all-cause mortality or progression-free mortality among *BRCA* mutation carriers \[[@R9]--[@R14]\], whereas *Kotsopoulos* et al. reported that the mortality risk in ovarian cancer patients was significantly poorer for *BRCA* mutation carriers than for non-carriers (HR = 1.67; 95% CI 1.34 to 2.08) \[[@R19]\]. The present meta-analysis with the largest number of patients investigated both survival (OS) and progression outcomes (PFS) for ovarian cancer, incorporating not only the general *BRCA* mutation status but also two subtypes, including *BRCA1* and *BRCA2* mutation status.

It has been reported that germline *BRCA1/2* mutations occur in approximately 10 to 20% of patients with invasive epithelial ovarian cancers \[[@R7], [@R9]--[@R14], [@R19]--[@R22]\], and more than 20% of patients with high-grade serous ovarian cancer \[[@R12]\]. *BRCA1/2* tumor suppressor genes are reported to be involved in DNA repair through homologous recombination, through which pathway genes are unable to repair DNA double-strand, resulting in genomic instability and having a tendency to malignant transformation \[[@R3]\]. On the other hand, the impairment of this pathway can also influence DNA cross-links by tumor cells, which can be induced by cisplatin, a chemotherapy agent for ovarian cancer. It has been indicated that *BRCA*-deficient patients can have better survival outcomes through the increase in the response rate to platinum-based chemotherapy \[[@R7], [@R8]\].

The findings of this updated meta-analysis are generally consistent with and further extend the other two published systematic reviews and meta-analyses in several important ways. First, our study had added greater statistical power to the associations between *BRCA* mutations and ovarian cancer survival with more detailed subgroup analyses. For example, the present meta-analysis involved approximately 2.3 times as many participants as the previous two studies \[[@R24], [@R25]\]. As a matter of fact, 11 recent published cohort studies were involved in the analyses. Second, three mutation subtypes (*BRCA1/2*, *BRCA1* and *BRCA2*) were thoroughly investigated in contrast to the earlier two meta-analyses (including only *BRCA1* and *BRCA2* subtypes). Thirdly, we did detailed subgroup analyses under a broader range of study level circumstances to examine the potential sources of heterogeneity. However, our findings concur with the previous meta-analyses. Inter-study heterogeneity was found very high for a number of analyses, which was probably due to the very variation in population characteristics and *BRCA* mutation detection methods.

Thus, caution is required when interpreting these findings. Moreover, one important advantage of this meta-analyses lies in that we have thoroughly tested the influence of publication bias through Begg\'s test, Egger\'s test and sensitivity analysis and confirmed the robustness of the findings.

Several limitations of this meta-analysis are required to be addressed. We acknowledge that the results of this meta-analysis were derived from published data rather than from studies of individual patient data. Thus, we could not obtained the detailed characteristics of each individual from the involved studies including patient age, tumor stage, sample size, and follow-up period, which to some extent were contributory factors to the heterogeneity, but an attempt was made to account for this variation by conducting subgroup analyses. Another potential limitation of the study is that we also include some conference abstracts in the analysis. It is likely that the results may differ to certain extent between the conference abstracts and future updated full publication. However, we proposed that such differences are very likely to be relatively mild. Moreover, the method for the detection of *BRCA* mutation varied among studies, which may also a source of substantial heterogeneity. Some of the included studies did not report complete data for analysis, and could have potentially affected the results of multivariate analysis. Most of the included studies adequately adjusted for some known confounders, in particular patients age, tumor stage and grade or chemotherapy. However, some studies did not assess these factors and we acknowledge this limitation. As these were all studies with small sample size, it is unlikely to have affected the results of the analysis substantially. Although no obvious evidence of publication bias was noted in each subset of meta-analysis, it was still a major concern. Due to the time taken to conduct this meta-analysis, further relevant studies concerning this topic may have been published. However, given the relative paucity of suitable studies identified through the last 20 years from 1996 to 2016, we proposed that there were probably very few studies in number and they would not substantially affect the general conclusions of this study.

Despite all of these limitations, however, our meta-analysis with a large sample size of over 18,396 participants, and used the appropriate analyses to investigate the heterogeneity and publication bias among the different studies, showed that in patients with ovarian cancer, *BRCA* mutation (irrespective of its subtypes) carriers had better OS and PFS than non-carriers. Whether the results may have therapeutic implications remains to be elucidated with further larger, well-designed studies in specific ovarian cancer patients.

MATERIALS AND METHODS {#s4}
=====================

Literature search and study selection {#s4_1}
-------------------------------------

PubMed and EMBASE were searched for studies published up to February 2016 for the following searching terms: (ovary/ovarian/oophor\* and cancer/neoplas\*/tumor\*/tumour\*/ cancer\*/carcinoma\*/malignan\*/neoplasms) and (*BRCA1/2* and mutation\*/mutated) and mortality/survival/prognosis. Mesh (Pubmed) and Emtree (Embase) terms combined with free text words were used for searching. Detailed search terms and strategies for the two databases are presented in [Supplementary Appendix 1](#SD1){ref-type="supplementary-material"}. In addition, we also conducted the manual searches of references in all eligible studies to identify potential missing publications that were not identified during the preliminary literature searches. We did not place any restrictions on the searches.

Studies were considered eligible if they met the following inclusion criteria: observational studies (cohort or case-control studies) that investigated patients with ovarian cancer assessed for *BRCA* mutation status (*BRCA1* or *BRCA2* mutation status). The outcome measures included OS and PFS, measured as the relative risk (RR), the odds ratio (OR), or the hazard ratio (HR) along with the 95% confidence interval (CI) (or sufficient data for calculating them). We did not include studies with unpublished data. If multiple reports contained the duplicated datasets, the report with the largest or the most recent data was included for analysis. Two investigators independently conducted the literature review (KX and SHY) and any discrepancies were resolved by discussion or by a senior investigator (YCZ).

Data extraction and quality assessment {#s4_2}
--------------------------------------

Two investigators independently extracted data from each included study using a predefined standardized data extraction form including the pertinent issues that concerned the characteristics and survival outcomes of the ovarian cancer patients. For each article, the following information was extracted: authors and published years, study design, sample size, inclusion period, research country, disease stage, tumor histology, *BRCA* mutation detection methods, research center involved, duration of follow-up and adjusted variables. The extracted data were crosschecked and any disagreements were resolved by discussion.

Outcome measures {#s4_3}
----------------

The primary outcome measure was OS defined as the time from initial ovarian cancer diagnosis to death due to any causes. Secondary outcome was PFS defined as the time from diagnosis to the first confirmed sign of cancer recurrence, or progression (disease relapse or metastasis) or death from any cause.

Quality assessment {#s4_4}
------------------

The nine-star Newcastle-ottawa Scale (NOS) \[[@R44]\] was used to assess the study quality for each study. Three domains associated with the selection of study population, data comparability and exposure (case-control studies) or outcome (cohort studies) assessment were evaluated. The NOS score ranged from 0 to 9 with a score \> 7 indicating high quality. Two investigators scored each study, and any discrepancies were resolved by a third investigator.

Statistical analysis {#s4_5}
--------------------

All statistical analyses were performed using Stata statistical software (version 12.0; Stata Corporation, College Station, TX, USA). Pooled HRs for OS and PFS with 95% CIs were calculated using random-effects model due to the potential substantial heterogeneity between studies \[[@R45]\]. Heterogeneity across studies was examined by I^2^ statistic with an I^2^ ≥ 50% indicating the presence of significant heterogeneity \[[@R46]\]. We further investigated potential heterogeneity by subgroup analyses stratified by study quality, tumor stage, study design, sample size, number of research center, duration of follow-up, baseline characteristics adjusted, mutation ratio and tumor histology for OS and PFS across *BRCA1/2*, *BRCA1* and *BRCA2* mutation subgroups. Publication bias was evaluated by observing the asymmetry of funnel plots and using the Begg-Mazumdar rank correlation test and Egger\'s test \[[@R47], [@R48]\]. The Duval and Tweedie trim-and-fill method was also applied to conduct sensitivity analysis \[[@R49]\]. A two-sided *P* ≤ 0.05 was considered statistically significant.
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CI

:   95% confidence interval

HR

:   hazard ratios

NOS

:   Newcastle-ottawa Scale

OS

:   overall survival

PRISMA

:   the Preferred Reporting Items for Systematic Reviews and Meta-Analyses

PFS

:   progression-free survival
